Drug intelligence / Profile preview

Ad-MIFi

Development stage: Preclinical
Modality: Adenoviral Vectors → Other Viral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intratumoral, Intravenous

Overview

Ad-MIFi is a gene therapy product comprising a recombinant, replication-deficient adenoviral vector encoding a microRNA targeting macrophage migration inhibitory factor (MIF). It is designed to downregulate MIF, a cytokine implicated in inflammatory processes, tumorigenesis, and immune evasion, by expressing MIF-targeting RNA interference molecules in target cells. The therapy aims to reduce pathological MIF levels in indications such as cancer or inflammatory diseases. The developer has primarily targeted solid tumors in preclinical and early clinical investigations.

Brand names: Ad-MIFi
Other names: Ad-MIFi

Targets

MIF (Oxidized macrophage migration inhibitory factor)

Beyond the preview

Go deeper on Ad-MIFi.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ad-MIFi.

Explore the full profile